Browse articles from EyeWorld.org on the topic of the cornea. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Keep up with ASCRS Annual Meeting coverage with EyeWorld Onsite
➤ Positive topline results from Phase 3 trial for TED drug with new delivery method
➤ FDA expands dosing interval for wet AMD, DME treatment
➤ IDE granted to noninvasive bioelectric stimulation therapy for dry AMD
➤ First patients dosed in Phase 3 corneal cell therapy
➤ TED investigational treatment fails to meet primary endpoint
➤ OTC eye drop recall after FDA enforcement report cites sterility concerns
➤ ASCRS news and events
Epithelial basement membrane dystrophy (EBMD) is a common corneal issue. Two experts discussed how this might present in patients and the number of treatment options available to address the condition, with surgeons often needing to use several different strategies.
“As we advance in medicine, the next frontier will be getting a true picture of the state of the patient—genetics, environment, and lifestyle—and using this to find the correct diagnosis and treatment,” said Julie Schallhorn, MD, as she introduced the articles in the Cornea section of the issue.
Biologics may dominate in the retina subspecialty, but cornea is beginning to see interest with these products as well, especially for immune-mediated or severe ocular surface diseases and even corneal dystrophies. Three physicians spoke to EyeWorld about the topic.
ASCRS Subspecialty Day will take place on Friday, April 10, ahead of the 2026 ASCRS Annual Meeting, and promises exciting content across the fields of cornea, glaucoma, and refractive surgery.
➤ First patient treated with novel crosslinking approach for refractive error
➤ Multisociety working group established to set guidelines for modern IOL classification
➤ FDA reduces clinical trial requirement for new drugs to one pivotal trial
➤ ASCRS news and events
➤ Enrollment complete in Phase 3 trial for wet AMD
➤ Dosing complete in Phase 1/2 trial for retinitis pigmentosa treatment
➤ First patient dosed in gene therapy study for optic nerve disorder
➤ Company news
➤ New drop for temporary presbyopia relief approved
➤ First-in-human results for accommodating IOL
➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy
➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
➤ FDA review extended for dry eye disease treatment
➤ Key data gathered for expected NDA submission
➤ Phase 2b results for GA treatment
➤ Phase 3 studies discontinued for thyroid eye disease
➤ ASCRS news and events
“To take something known and look at it from a new direction, to question our view of reality, to wonder, these are the strengths of children, but also of innovators,” said Julie Schallhorn, MD, introducing and commenting on the articles in the Cornea section of this issue.
